Colossal Hatches 26 Chicks in 3D-Printed Egg, Opening Path to Giant Moa Project

Private labs promising biological miracles are not new: in 1996 Scotland’s Roslin Institute cloned Dolly the sheep and sparked both optimism and push-back; in 2017 Children’s Hospital of Philadelphia grew premature lambs in a “biobag,” yet full ectogenesis remains elusive. Colossal’s egg fits this lineage—an engineering leap chasing a biological frontier while courting celebrity money and media buzz. It underscores two centennial trends: the convergence of synthetic biology and venture capital, and the shift from conserving existing biodiversity to attempting to edit or recreate it. If scalable, an artificial avian womb could transform conservation breeding and pharma protein factories; if over-sold, it risks repeating the fate of 19th-century “great auk revival” schemes—grand visions that delivered no birds. Whether 2126 sees wild “moa proxies” or just a footnote in tech finance will hinge less on shells than on unresolved genomic, ecological and ethical equations.